Pliant Therapeutics, Inc. (NASDAQ:PLRX) Receives Consensus Recommendation of Buy from Analysts

Pliant Therapeutics, Inc. (NASDAQ:PLRX – Get Free Report) has received an average rating of “Buy” from the nine brokerages that are covering the firm, MarketBeat.com reports. Nine equities research analysts have rated the stock with a buy recommendation. The average 12-month price objective among brokerages that have covered the stock in the last year is […]

Related Keywords

New York ,United States ,Canada ,China , ,Td Asset Management Inc ,Barclays Plc ,York State Common Retirement Fund ,Pliant Therapeutics Company Profile ,China Universal Asset Management Co ,Pliant Therapeutics Inc ,Needham Company ,Nasdaq ,Royal Bank ,York Mellon Corp ,Pliant Therapeutics ,Get Free Report ,New York Mellon Corp ,Management Inc ,Universal Asset Management ,New York State Common Retirement Fund ,Get Free ,Pliant Therapeutics Daily ,Nasdaq Plrx ,Plrx ,Medical ,Ratings ,Consensus ,